Antengene announces first patient dosed in Phase I ATTRACT study of ATG-201
The company announced dosing began on Nov. 5, 2026 in China. The study is being conducted in China and Australia, and ATG-201 has received Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with the Therapeutic Goods Administration.
Primary source
Company press release (PR Newswire), November 5, 2026
Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases
Machine-summarized from the source above; not independently reported. How we use automation